Myocardial fibrosis blunts nitric oxide synthase-related preload reserve in human dilated cardiomyopathy

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 284, Issue 1 53-1, 2003, Pages

  Bronzwaer, Jean G F ^a,b   Heymes, Christophe ^c   Visser, Cees A ^a,b   Paulus, Walter J ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Collagen; Diastole; Myocardial contraction

Indexed keywords

COLLAGEN; HEME OXYGENASE; NITRIC OXIDE SYNTHASE; SUBSTANCE P; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BALLOON OCCLUSION; CLINICAL ARTICLE; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; HEART CATHETERIZATION; HEART CONTRACTION; HEART DILATATION; HEART LEFT VENTRICLE; HEART MUSCLE BIOPSY; HEART MUSCLE FIBROSIS; HEART PRELOAD; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0037229875     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.00401.2002     Document Type: Article

References (39)

1. G-nitro-L-arginine methyl ester-induced hypertension: Novel molecular adaptation to systolic load in absence of hypertrophy. Circulation 101: 423-429, 2000.
2. Bloch W, Fleischmann BK, Lorke DE, Andressen C, Hops B, Hescheler J, and Addicks K. Nitric oxide synthase expression and role during cardiomyogenesis. Cardiovasc Res 43: 675-684, 1999.
3. Boffa JJ, Tharaux PL, Placier S, Ardaillou R, Dussaule JC, and Chatziantoniou C. Angiotensin II activates collagen type I gene in the renal vasculature of transgenic mice during inhibition of nitric oxide synthesis: Evidence for an endothelin-mediated mechanism. Circulation 100: 1901-1908, 1999.
4. Brahmajothi MV and Campbell DL. Heterogeneous basal expression of nitric oxide synthase and superoxide dismutase isoforms in mammalian heart: Implications for mechanisms governing indirect and direct nitric oxide-related effects. Circ Res 85:575-587, 1999.
5. Brilla CG, Funck RC, and Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 102: 1388-1393, 2000.
6. Bronzwaer JG, De Bruyne B, Ascoop CA, and Paulus WJ. Comparative effects of pacing-induced and balloon coronary occlusion ischemia on left ventricular diastolic function in man. Circulation 84: 211-222, 1991.
7. Bronzwaer JG, Zeitz C, Visser CA, and Paulus WJ. Endomyocardial nitric oxide synthase and the hemodynamic phenotypes of human dilated cardiomyopathy and of athlete's heart. Cardiovasc Res 55: 270-278, 2002.
8. Cotton JM, Kearney MT, MacCarthy PA, Grocott-Mason RM, McClean DR, Heymes C, Richardson PJ, and Shah AM. Effects of nitric oxide synthase inhibition on basal function and the force-frequency relationship in the normal and failing human heart in vivo. Circulation 104: 2318-2323, 2001.
9. Drexler H, Kastner S, Strobel A, Studer R, Brodde OE, and Hasenfuss G. Expression, activity and functional significance of inducible nitric oxide synthase in the failing human heart. J Am Coll Cardiol 32: 955-963, 1998.
10. Farquharson CA and Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 101:594-597, 2000.
11. Fukuchi M, Hussain SN, and Giaid A. Heterogeneous expression and activity of endothelial and inducible nitric oxide synthases in end-stage human heart failure: Their relation to lesion site and beta-adrenergic receptor therapy. Circulation 98: 132-139, 1998.
12. Heger J, Godecke A, Flogel U, Merx MW, Molojavyi A, Kuhn-Velten WN, and Schrader J. Cardiac-specific overexpression of inducible nitric oxide synthase does not result in severe cardiac dysfunction. Circ Res 90: 93-99, 2002.
13. Heymes C, Vanderheyden M, Bronzwaer JG, Shah AM, and Paulus WJ. Endomyocardial nitric oxide synthase and left ventricular preload reserve in dilated cardiomyopathy. Circulation 99: 3009-3016, 1999.
14. Higginbotham MB, Sullivan MJ, Coleman RE, and Cobb FR. Regulation of stroke volume during exercise in patients with severe left ventricular dysfunction: Importance of the Starling mechanism (Abstract). J Am Coll Cardiol 9: 58A, 1987.
15. Holubarsch C, Ruf T, Goldstein DJ, Ashton RC, Nickl W, Pieske B, Pioch K, Ludemann J, Wiesner S, Hasenfuss G, Posival H, Just H, and Burkhoff D. Existence of the Frank-Starling mechanism in the failing human heart. Investigations on the organ, tissue, and sarcomere levels. Circulation 94: 683-689, 1996.
16. Kanno S, Lee PC, Zhang Y, Ho C, Griffith BP, Shears LL, and Billiar TR. Attenuation of myocardial ischemia/reperfusion injury by superinduction of inducible nitric oxide synthase. Circulation 101: 2742-2748, 2000.
17. Loke KE, Laycock SK, Mital S, Wolin MS, Bernstein R, Oz M, Addonizio L, Kaley G, and Hintze TH. Nitric oxide modulates mitochondrial respiration in failing human heart. Circulation 100: 1291-1297, 1999.
18. Mancini GB, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, Wargovich TJ, Mudra H, Luscher TF, Klibaner MI, Haber HE, Uprichard AC, Pepine CJ, and Pitt B. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND Study. Circulation 94: 258-265, 1996.
19. Matsubara BB, Matsubara LS, Zornoff LA, Franco M, and Janicki JS. Left ventricular adaptation to chronic pressure overload induced by inhibition of nitric oxide synthase in rats. Basic Res Cardiol 93: 173-181, 1998.
20. Matter CM, Mandinov L, Kaufmann PA, Vassalli G, Jiang Z, and Hess OM. Effect of NO donors on LV diastolic function in patients with severe pressure-overload hypertrophy. Circulation 99: 2396-2401, 1999.
21. Mohri M, Tagawa H, Egashira K, and Takeshita A. Intracoronary enalaprilat improves metabolic coronary vasodilation in patients with idiopathic dilated cardiomyopathy. J Cardiovasc Pharmacol 35: 249-255, 2000.
22. Paulus WJ, Frantz S, and Kelly RA. Nitric oxide and cardiac contractility in human heart failure: Time for reappraisal. Circulation 104: 2260-2262, 2001.
23. Paulus WJ, Heyndrickx GR, Buyl P, Goethals MA, and Andries E. Wide-range load shift of combined aortic valvuloplasty-arterial vasodilation slows isovolumic relaxation of the hypertrophied left ventricle. Circulation 81: 886-898, 1990.
24. Paulus WJ, Vantrimpont PJ, and Shah AM. Acute effects of nitric oxide on left ventricular relaxation and diastolic distensibility in humans. Assessment by bicoronary sodium nitroprusside infusion. Circulation 89: 2070-2078, 1994.
25. Pinamonti B, Di Lenarda A, Sinagra G, and Camerini F. Restrictive left ventricular filling pattern in dilated cardiomyopathy assessed by Doppler echocardiography: Clinical, echocardiographic and hemodynamic correlations and prognostic implications. Heart Muscle Disease Study Group. J Am Coll Cardiol 22: 808-815, 1993.
26. Pinsky DJ, Patton S, Mesaros S, Brovkovych V, Kubaszewski E, Grunfeld S, and Malinski T. Mechanical transduction of nitric oxide synthesis in the beating heart. Circ Res 81: 372-379, 1997.
27. Prendergast BD, Sagach VF, and Shah AM. Basal release of nitric oxide augments the Frank-Starling response in the isolated heart. Circulation 96: 1320-1329, 1997.
28. Raju VS, Imai N, and Liang CS. Chamber-specific regulation of heme oxygenase-1 (heat shock protein 32) in right-sided congestive heart failure. J Mol Cell Cardiol 31: 1581-1589, 1999.
29. Recchia FA, McConnell PI, Loke KE, Xu X, Ochoa M, and Hintze TH. Nitric oxide controls cardiac substrate utilization in the conscious dog. Cardiovasc Res 44: 325-332, 1999.
30. Satoh M, Nakamura M, Tamura G, Makita S, Segawa I, Tashiro A, Satodate R, and Hiramori K. Inducible nitric oxide synthase and tumor necrosis factor-alpha in myocardium in human dilated cardiomyopathy. J Am Coll Cardiol 29: 716-724, 1997.
31. Senzaki H, Paolocci N, Gluzband YA, Lindsey ML, Janicki JS, Crow MT, and Kass DA. β-blockade prevents sustained metalloproteinase activation and diastolic stiffening induced by angiotensin II combined with evolving cardiac dysfunction. Circ Res 86: 807-815, 2000.
32. 2+ in intact cardiac myocytes. Circ Res 74: 970-978, 1994.
33. Siwik DA, Chang DL, and Colucci WS. Interleukin-1beta and tumor necrosis factor-alpha decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. Circ Res 86: 1259-1265, 2000.
34. Tomita H, Egashira K, Ohara Y, Takemoto M, Koyanagi M, Katoh M, Yamamoto H, Tamaki K, Shimokawa H, and Takeshita A. Early induction of transforming growth factor-beta via angiotensin II type I receptors contributes to cardiac fibrosis induced by long-term blockade of nitric oxide synthesis in rats. Hypertension 32: 273-279, 1998.
35. Trochu JN, Bouhour JB, Kaley G, and Hintze TH. Role of endothelium-derived nitric oxide in the regulation of cardiac oxygen metabolism: Implications in health and disease. Circ Res 87:1108-1117, 2000.
36. Weber KT. Targeting pathological remodeling: Concepts of cardioprotection and reparation. Circulation 102: 1342-1345, 2000.
37. Wittstein IS, Kass DA, Pak PH, Maughan WL, Fetics B, and Hare JM. Cardiac nitric oxide production due to angiotensin-converting enzyme inhibition decreases beta-adrenergic myocardial contractility in patients with dilated cardiomyopathy. J Am Coll Cardiol 38: 429-435, 2001.
38. Yamakado T, Takagi E, Okubo S, Imanaka-Yoshida K, Tarumi T, Nakamura M, and Nakano T. Effects of aging on left ventricular relaxation in humans. Analysis of left ventricular isovolumic pressure decay. Circulation 95: 917-923, 1997.
39. Zannad F, Alla F, Dousset B, Perez A, and Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: Insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 102: 2700-2706, 2000.